Eric D. Shaff - 24 Jun 2021 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role
Director
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
24 Jun 2021
Net transactions value
+$88,613
Form type
4
Filing time
28 Jun 2021, 07:15:17 UTC
Next filing
08 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $88,613 +8,888 $9.97 8,888 24 Jun 2021 Common Stock 8,888 $9.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022.